GSK•benzinga•
The FDA Has Accepted For Review GSK's Biologics License Application For The Use Of Depemokimab In Two Indications, The Prescription Drug User Fee Act Date Is 16 December 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 3, 2025 by benzinga